Actively Recruiting
Study of Glofitamab and Lenalidomide Treatment in Adults 18 to 80 Years With High-Risk Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With a BTK Inhibitor
Led by Peking University Third Hospital · Updated on 2026-03-10
43
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the combination of glofitamab and lenalidomide in patients with high-risk relapsed or refractory Mantle Cell Lymphoma MCL who have previously been treated with a BTK inhibitor. This phase 2, single-arm, open-label, multi-center clinical study aims to assess the best overall response rate BOR at the end of induction, along with safety profiles and potential biomarkers predicting treatment effects in this patient group. The treatment involves administering glofitamab intravenously along with oral lenalidomide taken by the patient. Before starting glofitamab, patients receive two intravenous doses of obinutuzumab as a pretreatment. Patients must have received at least one prior systemic therapy including a BTK inhibitor and show at least one high-risk feature such as blastoidpleomorphic variants, bulky disease, failure to achieve complete response with first-line treatment, or early disease progression. Participants will undergo assessments including PETCT scans evaluated by Lugano criteria to measure response. Researchers will monitor efficacy outcomes like overall response rate, complete response rate, duration of response, progression-free survival, and overall survival over up to 48 months. Safety monitoring and biomarker analysis, including circulating tumor DNA and metabolic tumor volume, will also occur during the study, which spans from screening through treatment and follow-up.
CONDITIONS
Brief Title
Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma
Research Team
H
Hongmei Jing
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here